Argus downgraded Silk Road Medical (SILK) to Sell from Buy, reflecting the company’s planned acquisition by Boston Scientific (BSX). Under the terms of the deal announced on June 18, Boston will pay $27.50 per Silk share and the firm recommends selling the shares, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILK:
- M&A News: Boston Scientific (NYSE:BSX) Will Acquire SILK For $1.2B
- Silk Road Medical downgraded to Hold from Buy at Lake Street
- Silk Road Medical to be acquired by Boston Scientific for $27.50 per share
- Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific
- Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.